Bayer stock falls 2.18 percent as US investment meets caution
Published on 10/05/2026 at 22:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer (ISIN DE000BAY0017) fell 2.18 percent to EUR 43.96 on Xetra on October 5, 2026, after the company announced a USD 2.2 billion pharmaceutical manufacturing investment in Ohio. Bayer published the investment announcement on October 2, 2026.
US investment meets a weaker share price
The New Albany site is designed to expand Bayer's pharmaceutical production in the United States, the company's largest pharmaceutical market. The investment gives the announcement a long-term operating dimension, but the stock's October 5 decline shows that investors also weighed near-term agricultural and litigation risks.
The share price remained EUR 10.04 below its 52-week high of EUR 53.92 and EUR 18.18 above its 52-week low of EUR 25.78. Bayer's market capitalization stood at EUR 43.2 billion on October 5, 2026.
Q2 sales reached EUR 10.872 billion
Bayer's Q2 2026 group sales increased 2.2 percent to EUR 10.872 billion on a currency and portfolio adjusted basis. EBITDA before special items rose 1.9 percent to EUR 2.144 billion, according to Bayer.
The latest quarterly figures create a clearer contrast with the stock move: operating performance improved on the reported Q2 comparison, while the daily share price fell 2.18 percent. The official Q2 2026 report also shows core earnings per share up 16.7 percent, reinforcing the importance of separating current operations from market concerns.
Analysts keep targets above EUR 58
Finanznachrichten reported on October 1, 2026, that JPMorgan kept Bayer at Overweight with a EUR 61 price target. The bank said early Q3 expectations could be too high because of timing effects in Crop Science, while its full-year estimates remained broadly unchanged.
The consensus published by Investing.com is Buy from 18 analysts, with 13 Buy ratings, 4 Holds and 1 Sell. The average 12-month target is EUR 58.22, with a high of EUR 70 and a low of EUR 46, placing the average target 32.44 percent above the October 5 price of EUR 43.96.
Q3 results are scheduled for November 3
Bayer's investor calendar lists the Q3 2026 results, media update and investor video call for November 3, 2026, according to the company's quarterly reports page. That date is the next scheduled checkpoint for Crop Science expectations and the group's full-year trajectory.
Bayer stock ends below EUR 44
Bayer stock stood at a closing price of EUR 43.96 on Xetra on October 5, 2026, with a market capitalization of EUR 43.2 billion.
Bayer stock key data
- Company: Bayer Aktiengesellschaft
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Trading venue: Xetra
- Price (as of October 5, 2026): EUR 43.96, closing price
- Market capitalization: EUR 43.2 billion (as of October 5, 2026)
- 52-week range: EUR 25.78-53.92 (as of October 5, 2026)
- Sector / Industry: Chemicals
- Index membership: DAX
Upcoming dates for Bayer stock
- November 3, 2026: Q3 2026 results, media update and investor video call
